Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics, Inc. director Stephanie Okey sold 6,333 shares of common stock in an open-market transaction on March 5, 2026 at $63.38 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025. After this transaction, she directly holds 8,000 PTC Therapeutics shares.
PTC Therapeutics executive Lee Scott Golden reported an open-market stock sale. On March 5, 2026, the company’s EVP & Chief Medical Officer sold 10,000 shares of PTC Therapeutics common stock at a price of $63.38 per share.
The sale was executed under a written Rule 10b5-1 trading plan that Golden adopted on December 4, 2025. After this transaction, Golden directly owns 79,944 shares of PTC Therapeutics common stock.
PTC THERAPEUTICS, INC. executive Neil Gregory Almstead, the Chief Technical Operations Officer, reported an indirect open-market sale of common stock by his spouse. On March 5, 2026, his spouse sold 3,989 shares of common stock at $63.38 per share in a sale classified as an open-market or private transaction.
This transaction was carried out under a written Rule 10b5-1 trading plan adopted by Almstead on November 26, 2025. Following the sale, his spouse held 2,737 shares of common stock indirectly, while Almstead held an additional 112,140 shares of common stock directly.
Fidelity Brokerage Services LLC filed a Form 144 proposing the sale of Common shares of PTCT. The notice lists restricted stock vesting events on 06/18/2024 (1,334 shares), 02/18/2025 (1,333 shares), 02/19/2025 (1,333 shares) and 01/03/2026 (2,333 shares). The filing identifies the sales agent and class of securities.
PTCT holders sold common stock in multiple transactions disclosed on Form 144. The excerpt lists sale lots by Neil G. Almstead and Zheng Y. Almstead between 01/06/2026 and 02/18/2026, including examples of 1,279 shares for $98,415.98 and 3,056 shares for $211,953.77.
The entries show routine dispositions tied to restricted stock vesting and ESPP purchases in prior years; amounts and prices are itemized per sale date.
Lee S. Golden reported sales of common stock under Rule 144. The filing shows sales of 1,340 shares on 01/06/2026 for $103,109.78, 642 shares on 01/07/2026 for $49,744.60, 866 shares on 01/08/2026 for $66,204.92, and 2,484 shares on 02/18/2026 for $172,281.80.
The filing also lists multiple prior restricted stock vesting entries issued by the company on various dates, including vesting quantities such as 1,287 on 01/09/2023 and 1,885 on 01/05/2024, shown as background to the sold securities.
PTC Therapeutics executive Mark Elliott Boulding, Executive VP and Chief Legal Officer, reported open-market sales of a total of 3,019 shares of common stock on February 19, 2026. The transactions, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2024, occurred at weighted-average prices of $68.54 and $69.82 per share, based on multiple trades within disclosed price ranges from $67.99 to $70.18. Following these sales, Boulding directly held 105,212 shares of PTC Therapeutics common stock.
PTC Therapeutics SVP and Chief Accounting Officer Christine Marie Utter reported an automatic sale of 2,494 shares of common stock. The shares were sold at an average price of $69.36 per share to cover tax withholding obligations tied to recently vested restricted stock units.
These shares relate to the vesting of 3,500 RSUs from a February 15, 2024 grant of 14,000 RSUs and 1,450 RSUs from a February 15, 2024 grant of 2,900 RSUs. After this tax-withholding sale, Utter directly holds 70,199 shares of PTC Therapeutics common stock.
PTC Therapeutics chief financial officer Pierre Gravier reported an automatic sale of 2,992 shares of common stock at $69.36 per share. After this transaction, he holds 87,318 shares directly. The shares were sold under an irrevocable sell-to-cover instruction to satisfy tax withholding on recently vested restricted stock units (RSUs) from prior grants.
PTC Therapeutics, Inc.'s chief business officer, Eric Pauwels, reported an automatic sale of 3,019 shares of common stock in an open-market transaction at a price of $69.36 per share. The sale was made under an irrevocable sell-to-cover election to satisfy tax withholding obligations upon the vesting of previously granted RSUs.
After this transaction, Pauwels directly holds 77,122 shares of PTC Therapeutics common stock. The sale reflects tax-related withholding rather than a discretionary reduction of his overall equity position.